EUCTR2013-005596-40-IT进行中（未招募）不适用
Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological centrally confirmed diagnosis of solitary fibrous tumor
- •Expression of PDGFRB and/or VEGFR2 by immunohistochemistry on formalin fixed-paraffin embedded (FFPE) material as minimal requirement. Activation of PDGFRB and/or VEGFR2 by real time PCR of PDGFB and VEGFA on FFPE material (if in sufficient quantity) or by biochemistry on frozen material (if available).
- •Locally advanced disease (i.e. surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or feasible, or easier, after cytoreduction) and/or metastatic disease
- •Measurable or evaluable disease
- •Evidence of progression by RECIST during the 6 months before study entry
- •1st-line vs 3-rd-line
- •Eastern Cooperative Oncology Group (ECOG) Performance Status = 0, 1, 2
- •Adequate bone marrow function, defined as the following: ANC >1.5 x 109/L, platelets >100 x 109/L, Hb >9 g/dL. Blood transfusions are allowed to reach the baseline requested Hb level
- •Adequate organ function, defined as the following: total bilirubin within normal institutional limits (but in case of Gilbert’s syndrome), AST (SGOT) and ALT (SGPT) <2.5 x UNL, creatinine <1.5 x ULN. within normal institutional limits or creatinine clearance ? ?60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- •Cardiac ejection fraction =50% as measured by echocardiogram
- •Age > 18 yrs
- •Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
- •No history of arterial and/or venous thromboembolic event within the previous 12 months.
- •Written, voluntary informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
- •Previous treatment with any other investigational or not investigational agents and or radiation therapy within 28 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •Major surgery within 2 weeks prior to study entry
- •Previous radiotherapy to ?25 % of the bone marrow
- •Concomitant other investigational agents or concurrent anticancer therapy. In addition, all herbal (alternative) medicines are excluded
- •Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., history of uncontrolled or symptomatic angina, history of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation, myocardial infarction < 6 months from study entry, uncontrolled or symptomatic congestive heart failure, ejection fraction below the institutional normal limit)
- •Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- •Known diagnosis of human immunodeficiency virus (HIV) infection
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Axitinib
- •Expected non-compliance to medical regimens
研究者
相似试验
进行中（未招募）
1 期
Axitinib Treatment for Widespread Kidney Cancer Unsuitable for SurgeryMetastatic renal cell carcinomaMedDRA version: 19.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2011-004562-16-GBInstitute of Cancer Research
进行中（未招募）
1 期
Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study)metastatic renal cell carcinoma (mRCC)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864CTIS2024-511397-70-00Consorzio Oncotech118
进行中（未招募）
1 期
A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas - Axi-STS Trial, version 1Soft tissue sarcomaEUCTR2008-006007-23-GBSheffield Teaching Hospitals NHS Foundation Trust152
进行中（未招募）
1 期
A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma.Advanced colorectal carcinomaMedDRA version: 14.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002384-16-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)49
已完成
2 期
A Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomyCancerISRCTN72679844Institute of Cancer Research (UK)65